Login to Your Account

Stressgen Reports Mixed HspE7 Data, Moves Drug Forward In RRP

By Karen Pihl-Carey

Thursday, February 26, 2004
Recurrent respiratory papillomatosis represents the first indication that Stressgen Biotechnologies Corp. intends to pursue with its drug HspE7, based on positive Phase II data released this week. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription